We have previously described in tuberous sclerosis (TSC) hamartomas the phenomenon of loss of heterozygosity (LOH) for DNA markers in the region of both the TSC2 gene on chromosome 16pl3.3 and the TSC1 gene on 9q34.
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We now describe the spectrum of LOH in 51 TSC hamartomas from 34 cases of TSC. DNA was extracted from leucocytes or normal paraffin embedded tissue, and from frozen paraffin embedded hamartoma tissue from the same patient. The samples were analysed for 11 markers spanning the TSC1 locus and nine markers spanning the TSC2 locus. Twenty-one of 51 hamartomas showed LOH (41%). There was significantly more LOH on 16pl3.3, with 16 hamartomas showing LOH around TSC2, and five in the vicinity of TSC1. No hamartoma showed LOH for markers around both loci. All the areas of LOH on chromosome 9 were large, but the smallest region of overlap lay between the markers D9S149 and D9S114, providing independent evidence for the localisation of the TSCl gene.
These data show that LOH is a common finding in a wide range of hamartomas, affecting the same TSC locus in different lesions from the same patient but not affecting both loci. These data support the hypothesis that both the TSC genes act as tumour suppressors and that the manifestations of TSC in patients with germline TSC mutations rise from "second hit" somatic mutations inactivating the remaining normal copy of the TSC gene. Tuberous sclerosis (TSC) is an autosomal dominant condition characterised by tumourlike malformations (hamartomas) of the skin, brain, heart, kidney, and other organs. The disease prevalence is estimated at 1 in 10 has a short area of homology to a RAP 1-GTPase activating protein (rap 1 GAP or GAP3), and the expressed TSC2 protein has raplGAP activity in vitro. 4 We and others have described the phenomenon of loss of heterozygosity (LOH) in the region of the TSC1 or TSC2 genes in hamartomas from cases of TSC.5-7 The presence of LOH on 16p 13.3 in TSC hamartomas, and the finding of large germline deletions in the TSC2 gene in cases ofTSC strongly suggest that the TSC2 gene acts as a tumour or growth suppressor, according to Knudson Loss of heterozygosity in tuberous sclerosis hamartomas |TSC1| |S64 S149 S1198 ABO S150 DBH S122 S66 S114 S298 S67 Twenty-one of 51 hamartomas showed LOH (41%) either in the region of the TSC 1 locus or the TSC2 gene. No hamartoma showed LOH for markers around both loci. Five lesions showed LOH for markers around TSC 1 (fig
-. 2) . A cortical tuber (TUB2) and cardiac rhabdomyoma (CRM) from the same case showed identical patterns of LOH and the same allele was lost in both hamartomas. The same phenomenon occurred in a shagreen patch and a cutaneous fibroma (FIB2 and SHP) from another case of TSC. We would interpret this finding cautiously, as the markers used represent discrete points along a genome, and the power of LOH studies is insufficient to map areas of somatic deletion effectively. There did not appear to be any major differences in the frequency of LOH between the different types of hamartoma. Seven of 17 renal angiomyolipomas showed LOH and five ofnine giant cell astrocytomas showed LOH. Three of eight fibromas, three of five cortical tubers, a shagreen patch, a cardiac rhabdomyoma, and a renal cell carcinoma showed LOH. There was significantly more LOH for markers in the region of the TSC2 gene, with a X2 of 7.52 and a p value of <0.007. This excess of LOH for 16pl3 .3 confirms data from other workers studying TSC hamartomas and sporadic renal angiomyolipomas9l0 and may simply reflect that the TSC 1 locus is less well defined, and therefore LOH for 9q34 is harder to find.
These data show that LOH is a common finding, occurring in seven different types of hamartoma, including brain hamartomas.
LOH occurs in the same TSC locus in different lesions from the same patient but does not affect both loci. These data support the hypothesis that both the TSC genes act as tumour suppressors, and that the manifestations of TSC in patients with germline TSC mutations arise from "second hit" somatic mutations inactivating the remaining normal copy of the TSC gene. Further LOH studies of TSC hamartomas will still be of benefit, as the finding angiomyolipoma, GCA =giant cell astrocytoma, RCC= renal cell carcinoma, TUB= tuber, CRM= cardiac rhabdomyoma, FIB =fibroma, SHP= shagreen patch. 
